REVOLUTION MEDICINES INC (RVMD)
US76155X1000 - Common Stock
We assign a fundamental rating of 4 out of 10 to RVMD. RVMD was compared to 588 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for RVMD as it has an excellent financial health rating, but there are worries on the profitability. RVMD is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
RVMD had negative earnings in the past year.
RVMD had a negative operating cash flow in the past year.
RVMD had negative earnings in each of the past 5 years.
In the past 5 years RVMD always reported negative operating cash flow.
1.2 Ratios
RVMD's Return On Assets of -21.17% is amongst the best of the industry. RVMD outperforms 80.99% of its industry peers.
The Return On Equity of RVMD (-23.89%) is better than 84.76% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -21.17% | ||
| ROE | -23.89% | ||
| ROIC | N/A |
ROA(3y)-25.72%
ROA(5y)-24.94%
ROE(3y)-30.41%
ROE(5y)-31.02%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
RVMD does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
RVMD does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, RVMD has more shares outstanding
Compared to 5 years ago, RVMD has more shares outstanding
RVMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 14.29 indicates that RVMD is not in any danger for bankruptcy at the moment.
RVMD has a better Altman-Z score (14.29) than 89.55% of its industry peers.
RVMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 14.29 |
ROIC/WACCN/A
WACC9.34%
2.3 Liquidity
A Current Ratio of 13.06 indicates that RVMD has no problem at all paying its short term obligations.
RVMD has a Current ratio of 13.06. This is amongst the best in the industry. RVMD outperforms 86.64% of its industry peers.
RVMD has a Quick Ratio of 13.06. This indicates that RVMD is financially healthy and has no problem in meeting its short term obligations.
RVMD has a Quick ratio of 13.06. This is amongst the best in the industry. RVMD outperforms 86.82% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 13.06 | ||
| Quick Ratio | 13.06 |
3. Growth
3.1 Past
The earnings per share for RVMD have decreased strongly by -21.71% in the last year.
The Revenue for RVMD has decreased by -67.30% in the past year. This is quite bad
The Revenue for RVMD have been decreasing by -10.50% on average. This is quite bad
EPS 1Y (TTM)-21.71%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-80.95%
Revenue 1Y (TTM)-67.3%
Revenue growth 3Y-35.41%
Revenue growth 5Y-10.5%
Revenue growth Q2Q-95.16%
3.2 Future
Based on estimates for the next years, RVMD will show a small growth in Earnings Per Share. The EPS will grow by 5.91% on average per year.
The Revenue is expected to grow by 117.62% on average over the next years. This is a very strong growth
EPS Next Y14.11%
EPS Next 2Y3.09%
EPS Next 3Y3.38%
EPS Next 5Y5.91%
Revenue Next Year-44.47%
Revenue Next 2Y-31.86%
Revenue Next 3Y21.07%
Revenue Next 5Y117.62%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for RVMD. In the last year negative earnings were reported.
Also next year RVMD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.09%
EPS Next 3Y3.38%
5. Dividend
5.1 Amount
No dividends for RVMD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
REVOLUTION MEDICINES INC
NASDAQ:RVMD (4/26/2024, 7:14:30 PM)
After market: 36.05 +0.09 (+0.25%)35.96
+0.63 (+1.78%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap5.92B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -21.17% | ||
| ROE | -23.89% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 13.06 | ||
| Quick Ratio | 13.06 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-21.71%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y14.11%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-67.3%
Revenue growth 3Y-35.41%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y